213 related articles for article (PubMed ID: 12195347)
1. Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment.
Marchetti G; Meroni L; Varchetta S; Terzieva V; Bandera A; Manganaro D; Molteni C; Trabattoni D; Fossati S; Clerici M; Galli M; Moroni M; Franzetti F; Gori A
J Infect Dis; 2002 Sep; 186(5):606-16. PubMed ID: 12195347
[TBL] [Abstract][Full Text] [Related]
2. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328.
Mitsuyasu R; Gelman R; Cherng DW; Landay A; Fahey J; Reichman R; Erice A; Bucy RP; Kilby JM; Lederman MM; Hamilton CD; Lertora J; White BL; Tebas P; Duliege AM; Pollard RB;
Arch Intern Med; 2007 Mar; 167(6):597-605. PubMed ID: 17389292
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART.
Marchetti G; Gori A; Casabianca A; Magnani M; Franzetti F; Clerici M; Perno CF; Monforte Ad; Galli M; Meroni L
AIDS; 2006 Aug; 20(13):1727-36. PubMed ID: 16931937
[TBL] [Abstract][Full Text] [Related]
4. Long-term clinical and surrogate marker effects of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients.
Herzmann C; Cuthbertson Z; Fosdick L; Fisher M; Nelson M; Perry N; Law M; Wand H; Janossy G; Johnson MA; Youle M
J Antimicrob Chemother; 2008 Sep; 62(3):583-6. PubMed ID: 18587135
[TBL] [Abstract][Full Text] [Related]
5. Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART.
Isgrò A; Leti W; De Santis W; Marziali M; Esposito A; Fimiani C; Luzi G; Pinti M; Cossarizza A; Aiuti F; Mezzaroma I
Clin Infect Dis; 2008 Jun; 46(12):1902-10. PubMed ID: 18462177
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulation induced by tucaresol in HIV infection: results of a 16 week pilot Phase I/II trial.
Gori A; Trabattoni D; Bandera A; Saresella M; Marchetti G; Gazzola L; Biasin M; Rhodes J; McDade H; Panebianco R; Galli M; Moroni M; Ferrante P; Thomas N; Franzetti F; Bray D; Clerici M
Antivir Ther; 2004 Aug; 9(4):603-14. PubMed ID: 15456092
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with Arnó A; Ruiz L; Juan M; Jou A; Balagué M; Zayat MK; Marfil S; Martínez-Picado J; Martínez MA; Romeu J; Pujol-Borrell R; Lane C; Clotet B
J Infect Dis; 1999 Jul; 180(1):56-60. PubMed ID: 10353861
[TBL] [Abstract][Full Text] [Related]
8. Low-dose IL-2 reduces lymphocyte apoptosis and increases naive CD4 cells in HIV-1 patients treated with HAART.
Pandolfi F; Pierdominici M; Marziali M; Livia Bernardi M; Antonelli G; Galati V; D'Offizi G; Aiuti F
Clin Immunol; 2000 Mar; 94(3):153-9. PubMed ID: 10692234
[TBL] [Abstract][Full Text] [Related]
9. Increase of HIV-1 pro-viral DNA per million peripheral blood mononuclear cells in patients with advanced HIV disease (CD4<200 cells/mm3) receiving interleukin 2 combined with HAART versus HAART alone (ANRS-082 trial).
Delaugerre C; Gourlain K; Tubiana R; Carcelain G; Marcelin AG; Chouquet C; Mouroux M; Duvivier C; Autran B; Costagliola D; Katlama C; Calvez V
Antivir Ther; 2003 Jun; 8(3):233-7. PubMed ID: 12924540
[TBL] [Abstract][Full Text] [Related]
10. T-cell homeostasis alteration in HIV-1 infected subjects with low CD4 T-cell count despite undetectable virus load during HAART.
Marziali M; De Santis W; Carello R; Leti W; Esposito A; Isgrò A; Fimiani C; Sirianni MC; Mezzaroma I; Aiuti F
AIDS; 2006 Oct; 20(16):2033-41. PubMed ID: 17053349
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapy.
Kovacs JA; Vogel S; Metcalf JA; Baseler M; Stevens R; Adelsberger J; Lempicki R; Hengel RL; Sereti I; Lambert L; Dewar RL; Davey RT; Walker RE; Falloon J; Polis MA; Masur H; Lane HC
Eur J Immunol; 2001 May; 31(5):1351-60. PubMed ID: 11465092
[TBL] [Abstract][Full Text] [Related]
12. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
Moore RD; Keruly JC
Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
[TBL] [Abstract][Full Text] [Related]
13. Immunophenotype of HIV+ patients during CD4 cell-monitored treatment interruption: role of the IL-7/IL-7 receptor system.
Nemes E; Lugli E; Nasi M; Ferraresi R; Pinti M; Bugarini R; Borghi V; Prati F; Esposito R; Cossarizza A; Mussini C
AIDS; 2006 Oct; 20(16):2021-32. PubMed ID: 17053348
[TBL] [Abstract][Full Text] [Related]
14. Effect of IL-2 on hepatitis C virus RNA levels in patients co-infected with human immunodeficiency virus receiving HAART.
Tedaldi EM; Chen L; Markowitz N; Kelly L; Abrams D;
J Viral Hepat; 2005 Jul; 12(4):414-20. PubMed ID: 15985013
[TBL] [Abstract][Full Text] [Related]
15. Premature immunosenescence in HIV-infected patients on highly active antiretroviral therapy with low-level CD4 T cell repopulation.
Molina-Pinelo S; Vallejo A; Díaz L; Soriano-Sarabia N; Ferrando-Martínez S; Resino S; Muñoz-Fernández MA; Leal M
J Antimicrob Chemother; 2009 Sep; 64(3):579-88. PubMed ID: 19608579
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of interleukin-7 receptor (CD127) in HIV infection is associated with T cell activation and is a main factor influencing restoration of CD4(+) cells after antiretroviral therapy.
Benito JM; López M; Lozano S; González-Lahoz J; Soriano V
J Infect Dis; 2008 Nov; 198(10):1466-73. PubMed ID: 18847371
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blinded, placebo-controlled trial of intermittent administration of interleukin-2 and prednisone in subjects infected with human immunodeficiency virus.
Tavel JA; Sereti I; Walker RE; Hahn B; Kovacs JA; Jagannatha S; Davey RT; Falloon J; Polis MA; Masur H; Metcalf JA; Stevens R; Rupert A; Baseler M; Lane HC
J Infect Dis; 2003 Aug; 188(4):531-6. PubMed ID: 12898439
[TBL] [Abstract][Full Text] [Related]
18. HIV-infected patients with a large thymus maintain higher CD4 counts in a 5-year follow-up study of patients treated with highly active antiretroviral therapy.
Kolte L; Ryder LP; Albrecht-Beste E; Jensen FK; Nielsen SD
Scand J Immunol; 2009 Dec; 70(6):608-13. PubMed ID: 19906203
[TBL] [Abstract][Full Text] [Related]
19. Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: the role of interleukin 7 and interleukin 7 receptor α and microbial translocation.
Rajasuriar R; Booth D; Solomon A; Chua K; Spelman T; Gouillou M; Schlub TE; Davenport M; Crowe S; Elliott J; Hoy J; Fairley C; Stewart G; Cameron P; Lewin SR
J Infect Dis; 2010 Oct; 202(8):1254-64. PubMed ID: 20812848
[TBL] [Abstract][Full Text] [Related]
20. Failure to reconstitute CD4+ T-cells despite suppression of HIV replication under HAART.
Aiuti F; Mezzaroma I
AIDS Rev; 2006; 8(2):88-97. PubMed ID: 16848276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
